Federal multidistrict litigation tracker

MDL 3094 Update — Ozempic / GLP-1 Lawsuit

In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation. Counts are monthly JPML snapshots and can change between reports.

Lawsuit status — November 2026

Ozempic / GLP-1 Lawsuit

Verified November 10, 2026

MDL: MDL-3094
Court: E.D. Pa.
Judge: Judge Karen Spencer Marston
Pending cases: 4,082; Count as of November 2, 2026 · Source; +57 since prior report
Current phase: Rule 702 motions; no ruling posted in public orders reviewed November 10, 2026
Settlement status: No public settlement program identified
Latest development: JPML reports 4,082 pending actions in MDL-3094 on November 2, 2026, up 57 from October 1; 4,196 total historical actions are reported separately.
Next major event: November 17, 2026 — Scheduled MDL status conference

What changed this month?

●JPML reports 4,082 pending actions in MDL-3094 on November 2, 2026, up 57 from October 1; 4,196 total historical actions are reported separately. Source
●Public orders reviewed November 10 show no later Rule 702 ruling. The amended conference order schedules November 17 and December 15 status conferences; these are not trials. Source
●The separate NAION vision-loss MDL-3163 has 278 pending actions as of November 2, 2026, compared with 247 on October 1. Source
●The public MDL-3094 orders page, checked October 23, lists the October 8 scheduling order for Rule 702 closing arguments on Cross Cutting Issues 2 and 3 but no ruling on those motions. Source
●An October 8 scheduling order sets closing arguments on the pending Rule 702 motions for Cross Cutting Issues 2 and 3 for October 13, 2026. The public orders page reviewed October 11 shows no Rule 702 ruling, bellwether trial date or settlement program. Source

MDL details

Created: February 2, 2024
Pending: 4,082
Total actions filed: 4,196
Monthly change: +57

Defendants named in the tracked record

Novo Nordisk (Ozempic, Wegovy, Rybelsus, Saxenda); Eli Lilly (Mounjaro, Zepbound, Trulicity). Defendants dispute the allegations.

Historical case counts

Report	Pending	Total filed
November 2, 2026	4,082	4,196
October 1, 2026	4,025	4,139
September 1, 2026	4,022	4,056
August 3, 2026	3,928	3,962

What the litigation alleges

The tracked claims concern prescription drug injury claim (federal mdl), including gastroparesis and severe gastrointestinal injuries. These are allegations; defendants dispute liability and causation.

Stage and bellwether status

The court held the Rule 702 evidentiary hearing on September 14–18, 2026. An October 8 order scheduled closing arguments for October 13. The public orders list reviewed November 10 contains no later Rule 702 ruling or bellwether trial setting. The April 30 amended conference order schedules a November 17, 2026 status conference at 1 p.m. in Courtroom 16B; the October 8 order leaves November and December conferences unchanged. A status conference or expert-evidence hearing is not a trial. NAION vision-loss claims proceed separately in MDL-3163.

Settlement status

The public MDL-3094 orders list reviewed November 10, 2026 does not announce a GLP-1 injury settlement program or official payout schedule. That public list is not a complete live PACER docket.

Individual claims: The Eastern District of Pennsylvania public MDL orders reviewed October 11, 2026 do not announce a GLP-1 injury settlement program or official payout amounts. The Rule 702 proceeding concerns expert evidence, not settlement eligibility or an individual award.